Abbott Laboratories– tag –
-
Smartwatches Revolutionize Blood Sugar Management: Dexcom G7 and FreeStyle Libre Enhance Apple Watch Integration, Expanding AI-Driven Ecosystem
TechRepublic USA Overview Smartwatches hold the potential to transform glucose tracking, but current advancements rely on the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and regulated healthcare tech... -
The Rise of Finger-Prick-Free Glucose Monitoring: Dexcom Stelo, Abbott Lingo, and the CGM Revolution in Metabolic Health
Mattioli 1885 イタリア Overview The U.S. FDA has approved a new generation of finger-prick-free continuous glucose monitors (CGMs) that measure interstitial fluid glucose and transmit real-time data to smartphones, largely eliminating da... -
CNET Names Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as Top Continuous Glucose Monitors for 2026, Setting New Standards in Blood Sugar Management
CNET USA Overview CNET's 2026 review identifies Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as leading continuous glucose monitoring (CGM) devices. These systems excel in sensor life, accuracy, and FDA approval status,... -
Abbott’s FreeStyle Libre Offers 10-Day Real-Time Glucose Monitoring for Diabetes Patients Aged 4 and Up
Health Insider Canada Overview Abbott Laboratories' FreeStyle Libre system provides continuous glucose monitoring for diabetes patients aged four and older, utilizing a small wearable sensor and a smartphone app. This system delivers rea... -
Non-Invasive Blood Sugar Monitoring Faces Accuracy and Reliability Hurdles; True Non-Invasive Devices Remain Undeveloped
Health.com USA Overview While non-invasive blood sugar meters hold promise for finger-prick-free glucose checks, most currently available devices fail to meet the expected medical-grade accuracy and reliability for daily tracking. Many p... -
Dorsey & Whitney Trust CO LLC Sells Abbott Laboratories Shares Amidst Focus on Libre Duo CE Mark Approval
MarketBeat USA Overview Dorsey & Whitney Trust CO LLC has reduced its holdings in Abbott Laboratories shares. Despite this divestment, Abbott is gaining significant attention for its recent CE Mark approval of Libre Duo, an innovativ... -
Erste Group Bank Adjusts Abbott’s FY2027 Earnings Outlook Downward, Highlights Libre Duo CE Mark as Key Growth Driver
MarketBeat USA Overview Erste Group Bank has slightly lowered its fiscal year 2027 earnings outlook for Abbott Laboratories, yet emphasizes Abbott's recent CE Mark approval for its innovative Libre Duo dual glucose-ketone sensing technol... -
Goodman Advisory Group Invests $1.29 Million in DexCom Amidst Strong Q1 Performance, Revenue Soars 15% to $1.19 Billion
MarketBeat USA Overview Goodman Advisory Group has made a strategic investment of $1.29 million in DexCom, a leading continuous glucose monitoring (CGM) company, following DexCom's strong first-quarter earnings report. The company achiev... -
Ultrahuman Launches M2 Live Metabolic Health Platform in U.S., Integrating Abbott’s OTC Lingo CGM for Prescription-Free Glucose Tracking
PR Newswire USA Overview Ultrahuman, a smart ring manufacturer, has launched 'M2 Live,' a metabolic health platform in the U.S. that integrates data from Abbott's over-the-counter (OTC) continuous glucose monitor (CGM) 'Lingo.' Available... -
Medtronic Enhances MiniMed 780G AID System with New CGM Sensors and Launches Screenless MiniMed Flex Pump
diaTribe.org USA Overview Medtronic has introduced two new continuous glucose monitor (CGM) sensors for its MiniMed 780G automated insulin delivery (AID) system in the U.S.: the 6-day Simplera Sync and the 15-day Instinct (based on Abbot...
